更正2：依维莫司（EVE）与依西美坦（EXE）用于≥65岁晚期乳腺癌患者：EVA研究为临床实践带来的新启示

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

作者信息

Cazzaniga Marina, Verusio Claudio, Ciccarese Mariangela, Fumagalli Alberto, Sartori Donata, Valerio Maria Rosaria, Airoldi Mario, Moretti Gabriella, Ficorella Corrado, Arcangeli Valentina, Diodati Lucrezia, Zambelli Alberto, Febbraro Antonio, Generali Daniele, Pistelli Mirco, Garrone Ornella, Musolino Antonino, Vici Patrizia, Maur Michela, Mentuccia Lucia, La Verde Nicla, Bianchi Giulia, Artale Salvatore, Blasi Livio, Piezzo Michela, Atzori Francesco, Turletti Anna, Benedetto Chiara, Cursano Maria Concetta, Fabi Alessandra, Gebbia Vittorio, Schirone Alessio, Palumbo Raffaella, Ferzi Antonella, Frassoldati Antonio, Scavelli Claudio, Clivio Luca, Torri Valter

机构信息

Research Unit Phase I trials, ASST Monza, Monza, Italy.

Oncology Unit, ASST Monza, Monza, Italy.

出版信息

Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431.

DOI:10.18632/oncotarget.26431

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6291174/

Abstract

[This corrects the article DOI: 10.18632/oncotarget.25874.].

摘要

[本文更正了文章的数字对象标识符：10.18632/oncotarget.25874。]

相似文献

1

Correction 2: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Oncotarget. 2018 Nov 30;9(94):36720-36721. doi: 10.18632/oncotarget.26431.

2

Correction: Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Oncotarget. 2018 Oct 2;9(77):34639-34640. doi: 10.18632/oncotarget.26213.

3

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study.

Breast. 2017 Oct;35:115-121. doi: 10.1016/j.breast.2017.06.043. Epub 2017 Jul 13.

4

Everolimus (EVE) and exemestane (EXE) in patients with advanced breast cancer aged ≥ 65 years: new lessons for clinical practice from the EVA study.

Oncotarget. 2018 Aug 7;9(61):31877-31887. doi: 10.18632/oncotarget.25874.

5

Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe.

J Med Econ. 2014 Dec;17(12):837-45. doi: 10.3111/13696998.2014.959589. Epub 2014 Sep 18.

6

Economic Evaluations of Everolimus Versus Other Hormonal Therapies in the Treatment of HR+/HER2- Advanced Breast Cancer From a US Payer Perspective.

Clin Breast Cancer. 2015 Oct;15(5):e263-76. doi: 10.1016/j.clbc.2015.04.001. Epub 2015 Apr 23.

7

Everolimus plus exemestane versus bevacizumab-based chemotherapy for second-line treatment of hormone receptor-positive metastatic breast cancer in Greece: An economic evaluation study.

BMC Health Serv Res. 2015 Aug 5;15:307. doi: 10.1186/s12913-015-0971-4.

8

A network meta-analysis of everolimus plus exemestane versus chemotherapy in the first- and second-line treatment of estrogen receptor-positive metastatic breast cancer.

Breast Cancer Res Treat. 2015 Jul;152(1):95-117. doi: 10.1007/s10549-015-3453-9. Epub 2015 Jun 5.

9

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

Breast Cancer Res Treat. 2017 Jun;163(3):587-594. doi: 10.1007/s10549-017-4213-9. Epub 2017 Mar 28.

10

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

Oncologist. 2017 Jun;22(6):648-654. doi: 10.1634/theoncologist.2016-0461. Epub 2017 Apr 21.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。